Kit for detecting fasciola hepatica based on RPA-CRISPR / Cas12a system

Through the RPA-CRISPR/Cas12a system kit, primers and crRNA are designed for ITS2 gene of H.p., and combined with Cas12a protein and fluorescent probe, the rapid and accurate detection of H.p., and the complex operation in the existing technology is solved. Sex and false positive problems are suitable for visual detection in areas with limited resources, with a detection limit of 0.122copies/μL.

CN119020506APending Publication Date: 2024-11-26JILIN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411389082.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-08
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing hepatic fluke detection methods have operational complexity and false positive problems, making it difficult to achieve fast, accurate and reliable early diagnosis. Especially in areas with limited resources, there is a lack of suitable visual kits and simple detection methods.

Method used

Using a kit based on the RPA-CRISPR/Cas12a system, the RPA primers and crRNA targeting the ITS2 gene of T. tumour s. Combining the Cas12a protein and fluorescent probe, the enrichment and detection of target DNA is achieved, providing fluorescent signals and lateral flow. Test strip probes achieve fast and visual detection results.

Benefits of technology

This method is simple to operate, has high specificity, does not require professional laboratories and expensive equipment, is suitable for areas with limited resources, and the detection limit reaches 0.122copies/μL. As a result, it can show bright white fluorescence under blue light or green fluorescence under purple light, through naked eyes Observe the results and avoid the occurrence of false positive results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020506A_ABST
    Figure CN119020506A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biology, and particularly discloses a kit for detecting fasciola hepatica based on an RPA-CRISPR / Cas12a system, which comprises a pair of RPA primers designed on the basis of the conserved sequence position of a fasciola hepatica ITS2 gene, Cas12a protein, crRNA designed on the basis of an ITS2 gene conserved site, a CRISPR / Cas12a protein reaction buffer solution, a fluorescent probe, a lateral flow test strip probe and a CRISPR single system detection test strip. The RPA primer sequences designed on the basis of the conserved sequence of the ITS2 gene of the fasciola hepatica are shown as SEQ ID NO.1-14, and the nucleotide sequences of the crRNA designed on the basis of the conserved site of the ITS2 gene are shown as SEQ ID NO.15-20; the kit does not need professional laboratories and expensive equipment and instruments, and is very suitable for rapid detection in regions with limited resources or laboratories with simple conditions.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a kit for detecting Fasciola hepatica based on an RPA-CRISPR / Cas12a system. Background Art

[0002] Fasciola hepatica is a foodborne zoonotic parasite and one of the most widely distributed trematodes in the world. It mainly causes fascioliasis in temperate climates, with lymnaeid snails as intermediate hosts. Fasciola hepatica can infect a variety of mammals, including humans, which not only endangers human health, but also affects the development of animal husbandry. The main infection sites are the liver and bile ducts of animals, leading to diseases such as hepatitis, cholangitis, and anemia. These symptoms are similar to those of other hepatobiliary diseases, and the inability to diagnose the disease in a timely, rapid, and effective manner leads to misdiagnosis. Therefore, there is an urgent need to develop a rapid, reliable, and accurate diagnostic method for the diagnosis of Fasciola hepatica infection, and early prevention of Fasciola hepatica infection is particularly important.

[0003] There are many detection methods for Fasciola hepatica infection on the market, such as traditional etiological examination methods, serological examination methods and molecular biological examination methods. Detection methods are the most basic tools for controlling parasitic infections. In the past few decades, the detection standard for Fasciola hepatica was usually diagnosed by examining the presence of its eggs in stool samples, such as using wet slides or concentration methods in stool, bile or duodenal fluid. However, the stool examination method can only detect eggs in the adult stage of Fasciola hepatica, which is not suitable for early diagnosis. Immunological examination methods, such as enzyme-linked immunosorbent assay (ELISA), indirect hemagglutination assay (IHA) and countercurrent immunoelectrophoresis, use the antigenic substances produced by the test after the invasion of the worm to stimulate the body to produce antibodies, thereby achieving the purpose of in vitro detection of Fasciola hepatica. Immunological detection of Fasciola hepatica infection has no limitation on the infection period, but the antigens of Fasciola hepatica are prone to cross-react with antibodies of other worms, resulting in low specificity of this method. In order to improve the limitations of the above detection methods, molecular biology-based methods have begun to be used in the field of liver fluke detection. As a mature biological diagnostic technology, polymerase chain reaction (PCR) technology and its variants (such as nested PCR, real-time PCR and multiplex PCR) have high sensitivity and specificity, but their dependence on professional personnel limits their ability to conduct large-scale field detection. Newly developed isothermal amplification technologies, such as loop-mediated isothermal amplification (LAMP), require a reaction temperature of 60-65°C, and the introduction of multiple primer pairs can easily lead to false positives. Recombinase polymerase amplification (RPA) can complete the reaction in about 30 minutes, but it is also easy to introduce false positive amplification. Therefore, due to the operational complexity and false positive problems of the above methods, it is necessary to establish a more convenient and fast detection method that does not rely on large instruments and operators, is particularly suitable for promotion in remote or resource-limited areas, and can detect liver fluke infection through naked eye diagnosis.

[0004] In recent years, the Cas nuclease diagnostic technology based on crRNA-guided clustered regularly interspaced short palindromic repeats (CRISPR) has attracted widespread attention due to its excellent specificity, sensitivity and reliability. Cas12a has a unique RuvC domain, and under the guidance of crRNA, it accurately recognizes the target DNA (18–25 nucleotides) to form a ternary complex, which activates the trans-cleavage activity of Cas12a and non-specifically cuts the single-stranded DNA in the system. At present, based on its trans-cleavage activity, CRISPR / Cas12a detection technology has shown superior diagnostic ability in the diagnosis of bacteria, viruses and parasites. Combined with the pre-amplification step of the RPA reaction to achieve enrichment of target DNA, CRISPR / Cas12a detection has been used to detect methicillin-resistant Staphylococcus aureus (MRSA) with a detection limit of 5 copies / μL. The established RPA-CRISPR / Cas12a platform was used to detect Plasmodium, achieving on-site detection with a detection limit of 1 copy / μL. Therefore, RPA-CRISPR / Cas12a technology has the potential to become a rapid, specific, and reliable field detection method for the prevention of Fasciola hepatica in resource-limited areas.

[0005] The liver fluke detection kit developed based on RPA-CRISPR / Cas12a technology can be observed under ultraviolet or blue light, or fluorescent signals can be collected through portable fluorescence detection equipment, and intuitive visualization results can also be obtained through CRISPR single system test strips. In view of the current lack of rapid visualization kits for clinical diagnosis of liver fluke infection, the present invention establishes a liver fluke visualization detection kit through RPA-CRISPR / Cas12a detection technology, and detects the collected clinical samples at the same time, which can realize the method of screening liver fluke infection in resource-poor areas, which is easier to promote at the grassroots level. Summary of the invention

[0006] The purpose of the present invention is to provide a kit for detecting Fasciola hepatica based on the RPA-CRISPR / Cas12a system in view of the defects of the prior art, so as to solve the problems raised by the above-mentioned background technology.

[0007] To achieve the above object, the present invention provides the following technical solutions: a kit for detecting Fasciola hepatica based on the RPA-CRISPR / Cas12a system, comprising a pair of RPA primers designed based on the conservative sequence position of the ITS2 gene of Fasciola hepatica, a Cas12a protein, a crRNA designed based on the conservative site of the ITS2 gene, a CRISPR / Cas12a protein reaction buffer, a fluorescent probe, a lateral flow test strip probe and a CRISPR single system detection test strip;

[0008] The RPA primer sequences designed based on the conservative sequence of the ITS2 gene of Fasciola hepatica are shown in SEQ ID NOs. 1 to 14, and the nucleotide sequences of the designed crRNAs designed based on the conservative sites of the ITS2 gene are shown in SEQ ID NOs. 15 to 20;

[0009] The sequence of the fluorescent probe in the kit is 5'-6-FAM-TTATT-BHQ1-3', the 5' end of which is modified with 6-carboxyfluorescein (6-FAM) and the 3' end is modified with a fluorescence quenching group (BHQ1); the sequence of the lateral flow test strip probe is 5'-6-FAM-TTATT-Biotin-3', the 5' end of which is modified with 6-carboxyfluorescein (6-FAM) and the 3' end is modified with biotin.

[0010] As a preferred technical solution of the present invention, the Cas12 protein is a Cas12a recombinant protein with a GST tag or a His tag.

[0011] As a preferred technical solution of the present invention, the RPA reaction system includes 2 μM forward primer and reverse primer, 14.75 μL Rehydration buffer, 2.5 μL template, and the remaining volume is made up with deionized water, with a total volume of 25 μL; the CRISPR / Cas12a reaction system includes 250M Cas12a protein, 250nM crRNA, 400nM fluorescent probe, 200nM directional flow test strip probe, 3.5 μL 10× reaction buffer, and the total reaction volume is 35 μL.

[0012] As a preferred technical solution of the present invention, the reaction buffer contains 50 mM Tris-HCl, 80 mM NaCl, 10 mM MgCl2 and 100 μg / ml recombinant albumin.

[0013] As a preferred technical solution of the present invention, a kit is used to detect the liver fluke genome, RPA targets the ITS2 sequence for specific pre-amplification, in order to provide a rich template for the CRISPR / Cas12a reaction, crRNA specifically recognizes the target sequence and enhances the specificity of the detection. The reaction is carried out at 37° C., the RPA pre-amplification time is 20 minutes, and the CRISPR / Cas12a reaction time is 40 minutes.

[0014] As a preferred technical solution of the present invention, when using the kit to detect the liver fluke genome, the RPA pre-amplification program is a constant temperature incubation at 37-39 degrees Celsius for 20-30 minutes; the CRISPR / Cas12a reaction program is a constant temperature reaction at 37 degrees Celsius in an EasyPGX quantitative PCR instrument for 40 minutes to 60 minutes; and the fluorescence signal is collected every 1 minute.

[0015] As a preferred technical solution of the present invention, when the kit is used to detect the liver fluke gene, the detection result of the fluorescent probe is read by a portable fluorescence detection device, the fluorescence curve of the positive sample increases, and the negative sample does not change; or irradiated under 365nm ultraviolet light and 470nm blue light, the positive sample shows white fluorescence under ultraviolet light, green fluorescence under blue light, and the negative sample is colorless; or combined with the CRISPR / Cas12a single system detection test strip, 50μL of reaction volume is added to the sample pad, and after 3-5 minutes, the positive sample shows a red strip on the T line, and the negative sample has no strip.

[0016] Compared with the prior art, the present invention has the following beneficial effects:

[0017] First: The RPA-CRISPR / Cas12a detection method of the present invention is simple to operate, has high specificity, has no cross-reaction with other pathogens, does not require a professional laboratory and expensive equipment and instruments, and is very suitable for rapid detection in resource-limited areas or laboratories with simple conditions.

[0018] Second: The RPA-CRISPR / Cas12a detection results of the present invention can show bright white fluorescence under blue light and bright green fluorescence under purple light, and the results can be directly observed by naked eyes. It can also be combined with lateral flow test strips, and the results can be observed by naked eyes by observing the T line and C line on the test strip.

[0019] Third: The RPA primer pair of the present invention is designed for the conserved gene ITS2 of Fasciola hepatica. No bands were amplified when using Diplocoel, Clonorchis sinensis, Giardia, Escherichia coli, Haemonchus contortus, Cryptosporidium parvum, Enterococcus faecalis, and Salmonella for amplification, which reflects the high specificity of the primers.

[0020] Fourth: The present invention has high sensitivity for the detection of Fasciola hepatica. By combining with a fluorescent reporter group, the detection limit can reach 0.122 copies / μL, and by combining with a lateral flow test strip reporter gene, the detection limit can reach 8.6 copies / μL.

[0021] Fifth: The present invention combines RPA amplification and CRISPR / Cas12a reaction into a "one-tube" reaction, places the RPA reaction at the bottom of the tube, and the CRISPR reaction at the tube cover, and adds the CRISPR reaction system to the RPA reaction system through a brief instant separation, thereby reducing the contamination caused by sampling during the actual sampling operation, avoiding the generation of false positive results, and making the results more accurate. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 This is the SDS-PAGE result diagram after purification of GST-LbCas12a protein of the present invention;

[0023] M: 10kDa-250kDa enzyme WJ102;

[0024] 1: supernatant after induction; 2-3: flow-through peak; 3-4: wash peak; 5-8: elution peak;

[0025] Figure 2 It is a protein immunoblot of GST-LbCas12a of the present invention;

[0026] Figure 3 The present invention uses crRNA and its target gene reported in other documents to verify the endonuclease activity of purified LbCas12a protein;

[0027] Figure 4 The present invention designs RPA primers for screening based on the conservative sequence of the ITS2 conservative gene of Fasciola hepatica;

[0028] Figure 5 This is a diagram showing the results of crRNA screening designed according to the conservative sequence of the ITS2 conservative gene of Fasciola hepatica in the present invention;

[0029] Figure 6 The RPA-CRISPR / Cas12a method established in the present invention compares the genomes of several selected pathogens and Fasciola hepatica, and collects fluorescent signals ( Figure 6 A), and continued to observe under ultraviolet and blue light conditions ( Figure 6 B) and observed by combining the test strips ( Figure 6 C);

[0030] Figure 7 Evaluation of the sensitivity of the RPA-CRISPR / Cas12a method established in the present invention, Figure 7 A is the visual fluorescence detection result. Figure 7 B is naked eye observation under ultraviolet and blue light; Figure 7 C is the KAPA analysis of 8 repeated experiments. Figure 7 D is the test result of lateral flow test strip;

[0031] Figure 8 The detection results of RPA-CRSIPR / Cas12a established in the present invention on the collected clinical samples, where Figure 8 A is the heat map analysis of the fluorescence signal; Figure 8 B is the test results of 143 sheep feces samples; Figure 8 C is the test results of 43 human stool samples; Figure 8 D is the test results of 143 sheep feces test strips and 43 human feces samples using CRISPR single system test strips;

[0032] Fig. 9 This is a diagram showing the test results of the nested PCR of the present invention on 143 sheep feces samples and human feces samples;

[0033] Fig.10 It is a detection flow chart of the present invention. DETAILED DESCRIPTION

[0034] The preferred embodiments of the present invention are described in detail below in conjunction with the accompanying drawings so that the advantages and features of the present invention can be more easily understood by those skilled in the art, thereby making a clearer and more definite definition of the protection scope of the present invention.

[0035] The present invention provides a technical solution: a kit for detecting liver fluke based on the RPA-CRISPR / Cas12a system, the kit comprising a pair of RPA primers designed based on the conservative sequence position of the liver fluke ITS2 gene, Cas12a protein, crRNA designed based on the conservative site of the ITS2 gene, CRISPR / Cas12a protein reaction buffer, fluorescent probe, lateral flow test strip probe and CRISPR single system detection test strip. Among them, the candidate specific primer sequences for RPA pre-amplification are shown in Table 1 SEQ ID NO.1~14, and the candidate crRNA sequences for CRISPR reaction are shown in Table 2 SEQ ID NO.15~20. The present invention is further described in detail below in conjunction with the accompanying drawings and examples.

[0036] Example 1: Purification and activity verification of LbCas12a protein;

[0037] The specific method is as follows:

[0038] 1. Construction of protein expression vector;

[0039] (1) The huLbCpf1 gene was amplified from 6His-MBP-TEV-huLbCpf1 (Plasmid #90096) by PCR and then connected to pGEX-4T-1 to construct the pGEX-4T-1-huLbCpf1 protein expression vector. The ligation product was transferred into the competent E. coli cell DH5α, plated on an LB plate containing ampicillin resistance and cultured overnight in a 37°C incubator. Single clones were picked for identification. The successfully identified plasmids were then transferred into the competent E. coli cell BL21. The successfully transformed colonies were picked and added to the LB medium containing ampicillin resistance. The culture was shaken overnight. The single clones were picked and added to the LB medium containing ampicillin resistance. The strains were preserved after activation.

[0040] 2. LbCas12a protein expression;

[0041] (1) Add LbCas12a protein expression plasmid;

[0042] (2) Take the overnight culture solution and add it to a 500 mL sterile LB incubator, add ampicillin resistance, and shake it in a 37°C incubator until the OD 600 =0.6;

[0043] (3) Add 500 μL of IPTG for induction, place in a 16°C constant temperature shaker for expansion culture, shake for 16-20 h, and collect the cells at a centrifugal speed of 8000 r / min;

[0044] (4) The cells were resuspended in 50 mL PBS and ultrasonically disrupted. The supernatant was collected after centrifugation at 8000 rpm at 4°C.

[0045] (5) The supernatant collected after ultrasonic disruption was added to a chromatography column filled with glutathione-agarose gel. After loading, the column was allowed to stand at 4°C for 2 h to allow the protein and filler to fully combine and release the supernatant at a rate of 4 to 5 s / drop;

[0046] (6) Pass 10 volumes of washing buffer (1× PBS) through the column to wash away impurities;

[0047] (7) The LbCas12a protein bound to the filler was eluted with elution buffer (0.1 g reduced glutathione, 30 mL 1×PBS). The eluted protein was diluted with sterile PBS and stored at -80°C with 10% glycerol for subsequent experiments;

[0048] (8) Take 80 μL of the sample from each step (4), (5), (6), and (7), add 15 μL of 6× protein loading buffer, boil at 100°C for 10 min, and then run SDS-PAGE electrophoresis to analyze the protein purification results.

[0049] 3. Activity verification of LbCas12a protein;

[0050] (1) The T1 target site with good cleavage reaction reported so far was used for the activity test of LbCas12a. The sequence of the T1 target is as follows:

[0051] T1-F: 5'-GCTTGTGGCCGTTTACGTCGCCGTCCAGCTCGACCAGGATGGG

[0052] CACCACCCCGGC-3'

[0053] T1-R: 5'-GCCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAA

[0054] ACGGCCACAAGC-3'

[0055] Obtain T1 target double-stranded DNA by annealing. The annealing system includes 10μL T2-F, 10μL T2-R, 10×5μL NEBufferr3.1, and the remaining volume is filled with deionized water. The total reaction volume is 50μL. The annealing program is 95℃ for 5min, and then slowly cooled to room temperature.

[0056] (2) According to the crRNA design principle of LbCas12a, crRNA-F is constructed using T7 promoter (TAATACGACTCACTATAGG) + LbCas12a scaffold sequence (aatttctactaagtgtagat) + target sequence (20-23bp after the target DNA PAM sequence), and the reverse complement is crRNA-R. Among them, the T7 promoter can be recognized by T7 RNA polymerase and transcribe the annealed double-stranded DNA fragment, and the scaffold sequence can bind to the LbCas12a protein. The crRNA-F and crRNA-R sequences are as follows:

[0057] T1-crRNA-F: 5'-GAAATTAATACGACTCACTATAGGGTAATTTCTACTAAGTGTAGATCGTCGCCGTCCAGCTCGACC-3'

[0058] T1-crRNA-R: 5'-GGTCGAGCTGGACGGCGACGATCTACACTTAGTAGAAATTACCCTATAGTGAGTCGTATTAATTTC-3'

[0059] (3) Measure the dsDNA concentration obtained after crRNA annealing by Nanodrop, and prepare the required reagents according to the T7 in vitro transcription system. Place the in vitro transcription system in a 37°C water bath and incubate for 3 to 4 hours. After completion, add DNase I and digest in a 37°C water bath for 15 minutes to remove the residual dsDNA in the system;

[0060] (4) purifying the product of (3) using the miRNeasy Mini Kit (Qiagen);

[0061] (5) Take 1 μL of the purified crRNA and place it in Nanodrop to measure the concentration, dilute it to 8000 nM with enzyme-free water and store it in liquid nitrogen for subsequent experiments;

[0062] (6) Verify the activity of LbCas12a protein. The annealed T1-dsDNA was added as a template, and the reaction system included 4 μL T1-dsDNA, 250 nM LbCas12a, 250 nM crRNA, 5× CRISPR reaction buffer, 400 nM fluorescent reporter group or 200 nM lateral flow test strip reporter group, and the remaining volume was filled with enzyme-free water. The reaction system was added to the EasyPGX fluorescent quantitative PCR instrument to collect the fluorescent signal every 1 min, and the device was not added with template dsDNA as a control group;

[0063] The results are as follows:

[0064] 1. SDS-PAGE analysis after GST-LbCas12a protein purification;

[0065] The purified protein was analyzed by SDS-PAGE and the target size was single ( Figure 1 ), and the purified GST-LbCas12a protein was incubated with GST antibody, and the protein band size was 170.3KD ( Figure 2 );

[0066] 2. Use the existing T1 target sequence and its crRNA to perform CRISPR reaction to verify the exosome activity of LbCas12a. Use the EasyPGX fluorescence quantitative PCR instrument to collect fluorescence signals every 1 min, and set a no-template group as a negative control group ( Figure 3 ).

[0067] Example 2: RPA-specific primers and crRNA screening;

[0068] Specific methods:

[0069] 1. Selection of target genes for Fasciola hepatica, design and screening of RPA primers;

[0070] (1) Acquisition of the conservative sequence of the target gene of Fasciola hepatica: The ITS2 sequence is highly conserved in Fasciola hepatica. Clinically, molecular biological detection such as nested PCR is established based on the ITS2 gene. The ITS2 gene exists in all stages of Fasciola hepatica. Therefore, this method finds its conservative gene site by comparing the ITS2 gene sequence of the clinical isolates of Fasciola hepatica on NCBI;

[0071] (2) Design and screening of RPA primers:

[0072] According to the primer design principle of RPA, 7 pairs of specific primers were designed on the conserved site of the ITS2 gene of Fasciola hepatica based on specific primers, and the primer specificity was verified by NCBI. The bands were analyzed by agarose gel electrophoresis, and the brightness of the amplified bands was observed under ultraviolet light. At the same time, a no-template group was set as a negative control.

[0073] 2. Design and screening of the optimal crRNA for Fasciola hepatica;

[0074] (1) According to the crRNA design principle of LbCas12a, three 20bp fragments depending on the PAM site were designed on the conserved sequence of the ITS2 gene of Fasciola hepatica. CrRNA-F was constructed using the T7 promoter (TAATACGACTCACTATAGG) + LbCas12a scaffold sequence (aatttctactaagtgtagat) + target sequence (20-23bp after the target DNA PAM sequence), and the reverse complement was crRNA-R. The sequences of crRNA1, crRNA2 and crRN3 are shown in XX, respectively. After crRNA-F / R was annealed, in vitro transcription was performed according to the method of Example 1 to obtain and then purify the crRNA;

[0075] (2) The product obtained by amplification of the optimal RPA primer selected in (1) was used as a template, and three groups of crRNAs including crRNA1, crRNA2 and crRN3 were added to the CRISPR reaction system respectively. The other components were 250nM Cas12a protein, 400nM fluorescent reporter group, 1×CRISPR reaction buffer, and the remaining volume was filled with enzyme-free water. The reaction mixture was placed in eight rows of qPCR, and the fluorescence data was collected every 1min using EasyPGX fluorescence quantitative PCR instrument. The optimal crRNA for liver fluke detection was screened according to the fluorescence intensity.

[0076] The results are as follows:

[0077] 1. Screening of the best RPA primer pairs for Fasciola hepatica detection;

[0078] According to the instructions of Twist Basic product, 7 pairs of RPA primers were designed on the conserved sequence of ITS2 gene of Fasciola hepatica. The sequences of 7 pairs of candidate primers (Primers set 1 to Primers set 7) are shown in Table 1 SEQ ID NO. 1 to 14. The amplified products were analyzed by agarose gel electrophoresis ( Figure 4 ), among which ITS2-F1 / R1 had the best amplification effect and was used in subsequent experiments.

[0079] Table 1: RPA candidate primer sequences

[0080]

[0081]

[0082] 2. Screening of the optimal crRNA for Fasciola hepatica detection;

[0083] Three pairs of crRNAs designed based on the conservative sequence of the ITS2 sequence of Fasciola hepatica were added to the CRISPR reaction system, and the reaction mixture was placed in the EasyPGX fluorescent quantitative PCR instrument, and the fluorescence was collected every 1 minute. The results showed that crRNA3 had the strongest fluorescence signal at the end point of 40 minutes ( Figure 5 ), were selected for subsequent experiments.

[0084] Table 2: Candidate sequences of crRNA

[0085]

[0086] Example 3: Specificity evaluation of the rapid visual detection method of Fasciola hepatica based on the RPA-CRISPR / Cas12a system;

[0087] The specific detection methods are as follows:

[0088] Based on the RPA primer pairs and crRNA screened in Example 2, the genomes of Fasciola hepatica, Giardia, Haemonchus contortus, Escherichia coli, Dicoelenterate, Salmonella, Cryptosporidium parvum, and Clonorchis sinensis were amplified respectively, and the RPA amplification products were taken and added to the CRISPR / Cas12a reaction system. The experimental results were observed by fluorescence signals, under ultraviolet and blue light, and on lateral flow test strips.

[0089] The results are as follows:

[0090] The detection results of the RPA-CRISPR / Cas12a system showed that the system had good specificity and had no cross-reaction with Giardia, Haemonchus contortus, Escherichia coli, Diplococcus, Salmonella, Cryptosporidium parvum, Clonorchis sinensis, etc. in the fluorescence detection system ( Figure 6 A), only Fasciola hepatica showed bright fluorescence under ultraviolet and blue light ( Figure 6 B) Combined with the CRISPR single system test strip, only Fasciola hepatica appears as a red band at the T line ( Figure 6 C).

[0091] Example 4: Sensitivity evaluation of the rapid visual detection method of Fasciola hepatica based on the RPA-CRISPR / Cas12a system;

[0092] The specific detection methods are as follows:

[0093] 1. Construct standard plasmid;

[0094] The ITS2 gene was amplified from the genome of Fasciola hepatica and connected to the pGEX-4T-1 plasmid to construct the pGEX-4T-1-ITS2 standard plasmid, which was then transferred into competent cells DH5α. After plating, the single colony with successful connection was picked out. After successful identification, the bacteria were shaken in LB medium containing ampicillin resistance and then stored. 10 μL of the bacterial storage solution was added to the LB medium containing ampicillin resistance and shaken in a 37°C shaker until the OD 600 =0.6, then the plasmid was extracted and the concentration was measured using Nanodrop.

[0095] 2. Using the most suitable RPA primer pair and crRNA screened in Example 2, the standard plasmid was diluted 10 times continuously as a template for RPA amplification, and then added to the CRISPR reaction system, and the fluorescence signal was collected by a fluorescence quantitative PCR instrument, and naked eye visualization was also performed under ultraviolet and blue light. In addition, the binding reaction product was also added to the lateral flow test strip, and the positive and negative samples were judged by visually observing whether the T line and C line appeared.

[0096] The results are as follows:

[0097] The standard plasmid pGEX-4T-1-ITS2 was diluted 10 times in a row, and the results of RPA-CRISPR / Cas12a detection showed that the fluorescence signal collected by the fluorescence quantitative PCR instrument detected 8.6×10 -1 copies / μL( Figure 7 A), naked eye visualization under UV and blue light also detected 8.6×10 -1 copies / μL( Figure 7 B). Kapa analysis was performed on 8 replicates of the sample, and the results showed that the minimum detection limit was 0.122 copies / μL ( Figure 7 C). Combined with the CRISPR single system test strip, the lowest detection limit is 8.6×10 0 copies / μL( Figure 7 D).

[0098] Example 5: Detection of clinical samples;

[0099] The specific operation method is as follows:

[0100] (1) The genomes of 143 sheep fecal samples (Changchun City, Jilin Province) and 43 human fecal swabs (provided by a hospital in Changchun) were extracted using a fecal genomic DNA extraction kit, and the extracted genome concentrations were quantified using Nanodrop.

[0101] (2) Using the optimal RPA primers and crRNA screened in Example 2, extract the genome of 186 stool samples for amplification, take the RPA amplification product and add it to the CRISPR reaction system, place it in a fluorescent quantitative PCR instrument for 40 minutes to collect the fluorescent signal, and judge the positive and negative of the sample by the fluorescence curve result. After the reaction is completed, the product is placed under ultraviolet and blue light to observe the results, and combined with the lateral flow test strip, the sample is observed by naked eyes after 5 minutes of dripping.

[0102] (3) Detect the samples using the established nested PCR method and compare the detection results.

[0103] The results are as follows:

[0104] 1: Using the optimal RPA primers and crRNA screened in Example 2, according to TwistAmp TM Basic product manual, amplify the genomes of 143 sheep fecal samples and 43 human fecal samples, add the amplified products to the CRISPR / Cas12a reaction system, place them in a fluorescent quantitative PCR instrument to collect fluorescent signals every 1 minute, and determine the positive and negative samples of Fasciola hepatica based on the fluorescent signals ( Figure 8 A); all samples were placed under UV and blue light to observe the visible fluorescence with naked eyes ( Figure 8 A- Figure 8 B); Combined with lateral flow test strips, observe sample detection ( Figure 8 C) The detection rate of Fasciola hepatica in sheep was 53.85% (77 / 143) and the detection rate of Fasciola hepatica in random human feces was 18.60% (8 / 43).

[0105] 2: 143 sheep feces samples and 43 human feces samples were tested using the established nested PCR and compared with the RPA-CRISPR / Cas12a method (Table 3, Fig. 9 ), and the results showed that the consistency rate between the nested PCR detection results and the RPA-CRISPR / Cas12a detection method was 98.39% (183 / 186).

[0106] Table 3: Results of nested PCR and RPA-CRISPR / Cas12a testing of clinical samples

[0107]

[0108] The above embodiments only express the implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention.

Claims

1. A kit for detecting Fasciola hepatica based on the RPA-CRISPR / Cas12a system, characterized in that: It includes a pair of RPA primers designed based on the conservative sequence position of the ITS2 gene of Fasciola hepatica, Cas12a protein, crRNA designed based on the conservative site of the ITS2 gene, CRISPR / Cas12a protein reaction buffer, fluorescent probe, lateral flow test strip probe and CRISPR single system detection test strip; The RPA primer sequences designed based on the conservative sequence of the ITS2 gene of Fasciola hepatica are shown in SEQ ID NOs. 1 to 14, and the crRNA nucleotide sequences designed based on the conservative site of the ITS2 gene are shown in SEQ ID NOs. 15 to 20; The sequence of the fluorescent probe in the kit is 5'-6-FAM-TTATT-BHQ1-3', the 5' end of which is modified with 6-carboxyfluorescein (6-FAM) and the 3' end is modified with a fluorescence quenching group (BHQ1); the sequence of the lateral flow test strip probe is 5'-6-FAM-TTATT-Biotin-3', the 5' end of which is modified with 6-carboxyfluorescein (6-FAM) and the 3' end is modified with biotin.

2. The kit for detecting Fasciola hepatica based on the RPA-CRISPR / Cas12a system according to claim 1, characterized in that: The Cas12 protein is a Cas12a recombinant protein with a GST tag or a His tag.

3. The kit for detecting Fasciola hepatica based on the RPA-CRISPR / Cas12a system according to claim 1, characterized in that: The RPA reaction system includes 2μM forward primer and reverse primer, 14.75μL Rehydration buffer, 2.5μL template, and the remaining volume is filled with deionized water, with a total volume of 25μL; the CRISPR / Cas12a reaction system includes 250M Cas12a protein, 250nM crRNA, 400nM fluorescent probe, 200nM directional flow test strip probe, 3.5μL 10× reaction buffer, and the total reaction volume is 35μL.

4. The kit for detecting Fasciola hepatica based on the RPA-CRISPR / Cas12a system according to claim 3, characterized in that: The reaction buffer contained 50 mM Tris-HCl, 80 mM NaCl, 10 mM MgCl2 and 100 μg / ml recombinant albumin.

5. The kit for detecting Fasciola hepatica based on the RPA-CRISPR / Cas12a system according to claim 1, characterized in that: The kit was used to detect the Fasciola hepatica genome. RPA targeted the ITS2 sequence for specific pre-amplification to provide abundant templates for the CRISPR / Cas12a reaction. crRNA specifically recognized the target sequence to enhance the specificity of the detection. The reaction was carried out at 37°C. The RPA pre-amplification time was 20 minutes and the CRISPR / Cas12a reaction time was 40 minutes.

6. The kit for detecting Fasciola hepatica based on the RPA-CRISPR / Cas12a system according to claim 1, characterized in that: When using the kit to detect the liver fluke genome, the RPA pre-amplification program is a constant temperature incubation at 37-39 degrees Celsius for 20-30 minutes; the CRISPR / Cas12a reaction program is a constant temperature reaction at 37 degrees Celsius in an EasyPGX quantitative PCR instrument for 40 minutes to 60 minutes; and the fluorescence signal is collected every 1 minute.

7. The kit for detecting Fasciola hepatica based on the RPA-CRISPR / Cas12a system according to claim 1, characterized in that: When using the kit to detect the liver fluke gene, the detection results of the fluorescent probe are read through a portable fluorescence detection device. The fluorescence curve of the positive sample increases, while the negative sample remains unchanged; or irradiated under 365nm ultraviolet light and 470nm blue light, the positive sample shows white fluorescence under ultraviolet light and green fluorescence under blue light, and the negative sample is colorless; or combined with the CRISPR / Cas12a single system detection test strip, 50μL of reaction volume is added to the sample pad. After 3-5 minutes, the positive sample shows a red strip on the T line, and the negative sample has no strip.